KARSEN PERRY A 4
4 · Intellia Therapeutics, Inc. · Filed Dec 18, 2020
Insider Transaction Report
Form 4
KARSEN PERRY A
Director
Transactions
- Exercise/Conversion
Common Stock
2020-12-17$25.98/sh+19,000$493,620→ 74,764 total - Exercise/Conversion
Common Stock
2020-12-17$15.78/sh+19,000$299,820→ 93,764 total - Sale
Common Stock
2020-12-17$52.52/sh−21,978$1,154,285→ 71,786 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−19,000→ 0 totalExercise: $14.35Exp: 2027-05-17→ Common Stock (19,000 underlying) - Exercise/Conversion
Common Stock
2020-12-17$14.35/sh+19,000$272,650→ 55,764 total - Sale
Common Stock
2020-12-17$53.69/sh−45,450$2,440,211→ 26,336 total - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−19,000→ 0 totalExercise: $25.98Exp: 2028-05-16→ Common Stock (19,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−19,000→ 0 totalExercise: $15.78Exp: 2029-05-20→ Common Stock (19,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2020-12-17−31,764→ 0 totalExercise: $18.00Exp: 2026-05-04→ Common Stock (31,764 underlying) - Exercise/Conversion
Common Stock
2020-12-17$18.00/sh+31,764$571,752→ 36,764 total - Sale
Common Stock
2020-12-17$54.33/sh−21,336$1,159,185→ 5,000 total
Footnotes (8)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.02 to $53.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.09 to $54.08, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.10 to $54.48, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price.
- [F5]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 5, 2019.
- [F6]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 17, 2018.
- [F7]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 17, 2019.
- [F8]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 21, 2020.